Display options
Cite
Kotsinas A, Papanagnou P, Evangelou K, et al. ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis. Front Genet. 2014;5:236doi: 10.3389/fgene.2014.00236.
Kotsinas, A., Papanagnou, P., Evangelou, K., Trigas, G. C., Kostourou, V., Townsend, P., & Gorgoulis, V. G. (2014). ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis. Frontiers in genetics, 5236. https://doi.org/10.3389/fgene.2014.00236
Kotsinas, Athanassios, et al. "ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis." Frontiers in genetics vol. 5 (2014): 236. doi: https://doi.org/10.3389/fgene.2014.00236
Kotsinas A, Papanagnou P, Evangelou K, Trigas GC, Kostourou V, Townsend P, Gorgoulis VG. ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis. Front Genet. 2014 Jul 22;5:236. doi: 10.3389/fgene.2014.00236. eCollection 2014. PMID: 25101116; PMCID: PMC4106421.
Copy Download .nbib Format: NLM
Share it on

Front Genet. 2014 Jul 22;5:236. doi: 10.3389/fgene.2014.00236. eCollection 2014.

ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis.

Frontiers in genetics

Athanassios Kotsinas, Panagiota Papanagnou, Konstantinos Evangelou, George C Trigas, Vassiliki Kostourou, Paul Townsend, Vassilis G Gorgoulis

Affiliations

  1. Molecular Carcinogenesis Group, Department of Histology and Embryology, School of Medicine, University of Athens Athens, Greece.
  2. Vascular Adhesion Lab, Biomedical Sciences Research Center Alexander Fleming Athens, Greece.
  3. Faculty Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre Manchester, UK ; Manchester Centre for Cellular Metabolism, University of Manchester, Manchester Academic Health Science Centre Manchester, UK.
  4. Molecular Carcinogenesis Group, Department of Histology and Embryology, School of Medicine, University of Athens Athens, Greece ; Faculty Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre Manchester, UK ; Manchester Centre for Cellular Metabolism, University of Manchester, Manchester Academic Health Science Centre Manchester, UK ; Biomedical Research Foundation, Academy of Athens Athens, Greece.

PMID: 25101116 PMCID: PMC4106421 DOI: 10.3389/fgene.2014.00236

Abstract

Alternative reading frame (ARF) is a tumor suppressor protein that senses oncogenic and other stressogenic signals. It can trigger p53-dependent and -independent responses with cell cycle arrest and apoptosis induction being the most prominent ones. Other ARF activities, particularly p53-independent ones, that could help in understanding cancer development and provide potential therapeutic exploitation are underrated. Although ARF is generally not expressed in normal tissues, it is essential for ocular and male germ cells development. The underlying mechanism(s) in these processes, while not clearly defined, point toward a functional link between ARF, DNA damage and angiogenesis. Based on a recent study from our group demonstrating a functional interplay between ataxia-telangiectasia mutated (ATM) and ARF during carcinogenesis, we discuss the role of ARF at the crossroads of cancer and developmental processes.

Keywords: ARF; ATM; angiogenesis; involution; meiosis; ocular development; spermatogenesis; vascular network

References

  1. Cell Stem Cell. 2008 Feb 7;2(2):170-82 - PubMed
  2. Mol Cancer Ther. 2009 Oct;8(10):2894-902 - PubMed
  3. Mol Cell. 2003 Feb;11(2):415-24 - PubMed
  4. J Natl Cancer Inst. 2012 Jan 18;104(2):93-113 - PubMed
  5. Curr Med Chem. 2007;14(17):1815-27 - PubMed
  6. Gynecol Oncol. 2010 Jun;117(3):497-504 - PubMed
  7. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3848-53 - PubMed
  8. Genes Dev. 1996 Oct 1;10(19):2411-22 - PubMed
  9. PLoS Genet. 2011 Jul;7(7):e1002157 - PubMed
  10. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7689-94 - PubMed
  11. Epigenetics. 2010 May 16;5(4):255-66 - PubMed
  12. Cancer Res. 2010 Jun 1;70(11):4749-58 - PubMed
  13. Nat Rev Cancer. 2003 Jun;3(6):401-10 - PubMed
  14. Nat Rev Drug Discov. 2004 May;3(5):391-400 - PubMed
  15. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13084-9 - PubMed
  16. Genes Dev. 1998 Aug 1;12(15):2424-33 - PubMed
  17. J Pathol. 2012 Jul;227(3):298-305 - PubMed
  18. Curr Mol Med. 2012 Jul 1;12(6):704-15 - PubMed
  19. EMBO J. 2005 Aug 3;24(15):2803-14 - PubMed
  20. Genes Dev. 1998 Aug 1;12(15):2434-42 - PubMed
  21. Cancer Res. 1999 May 1;59(9):2217-22 - PubMed
  22. Nat Rev Genet. 2002 Oct;3(10):790-801 - PubMed
  23. Nat Cell Biol. 2013 Aug;15(8):967-77 - PubMed
  24. Genes Dev. 2000 Sep 15;14(18):2358-65 - PubMed
  25. Eur Respir Rev. 2014 Mar 1;23(131):79-91 - PubMed
  26. Nat Rev Cancer. 2006 Sep;6(9):663-73 - PubMed
  27. Cell Cycle. 2014;13(8):1227-36 - PubMed
  28. J Biol Chem. 2001 Jul 27;276(30):28421-9 - PubMed
  29. PLoS One. 2010 Aug 27;5(8):e12454 - PubMed
  30. Cell Cycle. 2005 Oct;4(10):1316-9 - PubMed
  31. Cell. 1996 Jul 12;86(1):159-71 - PubMed
  32. Int J Cancer. 2011 Apr 15;128(8):1989-95 - PubMed
  33. Nature. 1998 Sep 10;395(6698):125-6 - PubMed
  34. Development. 1998 Oct;125(20):4007-17 - PubMed
  35. Eur J Cancer. 2005 Nov;41(16):2403-14 - PubMed
  36. Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6285-90 - PubMed
  37. Mol Biol Cell. 2004 May;15(5):2302-11 - PubMed
  38. Development. 2009 Jun;136(12):2081-9 - PubMed
  39. Mediators Inflamm. 2012;2012:568783 - PubMed
  40. Nat Med. 2012 Aug;18(8):1184-5 - PubMed
  41. J Am Coll Cardiol. 2010 May 18;55(20):2258-68 - PubMed
  42. Cell. 1995 Dec 15;83(6):993-1000 - PubMed
  43. Curr Opin Genet Dev. 2003 Feb;13(1):77-83 - PubMed

Publication Types